

Arun D. Singh  
A. Linn Murphree  
Bertil E. Damato  
*Editors*

# Clinical Ophthalmic Oncology

Retinoblastoma

Second Edition

 Springer

---

# Clinical Ophthalmic Oncology



---

Arun D. Singh • A. Linn Murphree  
Bertil E. Damato  
Editors

# Clinical Ophthalmic Oncology

Retinoblastoma

Second Edition

 Springer

*Editors*

Arun D. Singh, MD  
Department of Ophthalmic Oncology  
Cole Eye Institute  
Cleveland Clinic Foundation  
Cleveland, OH  
USA

Bertil E. Damato, MD, FRCS  
University of California  
San Francisco, CA  
USA

A. Linn Murphree, MD  
Department of Ophthalmology  
Children's Hospital Los Angeles  
Los Angeles, CA  
USA

ISBN 978-3-662-43450-5      ISBN 978-3-662-43451-2 (eBook)  
DOI 10.1007/978-3-662-43451-2  
Springer Heidelberg New York Dordrecht London

Library of Congress Control Number: 2014952602

© Springer-Verlag Berlin Heidelberg 2015

First edition originally published by © Saunders, 2007

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

---

## Preface

The management of patients with an ophthalmic tumor presents particular challenges. Ophthalmic tumors are rare and diverse so that their diagnosis can be quite complex. Treatment usually requires special expertise and equipment and, in many instances, is controversial. The field is advancing rapidly because of accelerating progress in tumor biology, pharmacology, and instrumentation. Increasingly, the care of patients with an ocular or adnexal tumor is provided by a multidisciplinary team comprising of ocular oncologists, general oncologists, radiotherapists, pathologists, psychologists, and other specialists. Therefore, several chapters authored by radiation oncologists, pediatric oncologists, hematologist-oncologists, and medical geneticists have been included to provide a broader perspective. For all these reasons, we felt that there was a continued need for a textbook of ophthalmic oncology, which would amalgamate knowledge from several different disciplines, thereby helping the various specialists to understand each other better and to cooperate more efficiently, eventually moving ophthalmic oncology in the realm of evidence-based medicine.

As several important studies have been published in recent years, the purpose of *Clinical Ophthalmic Oncology* (2<sup>nd</sup> edition) is to provide up-to-date information of the whole spectrum of the eyelid, conjunctival, intraocular, and orbital tumors, including basic principles of chemotherapy, radiation therapy, cancer epidemiology, angiogenesis, and cancer genetics. Several chapters authored by radiation oncologists, medical physicists, pediatric oncologists, hematologist-oncologists, and medical geneticists have been included to provide a broader perspective.

Although each section of *Clinical Ophthalmic Oncology* now represents a stand-alone volume, each chapter has a similar layout with boxes that highlight key features, tables that provide comparison, and flow diagrams that outline therapeutic approaches. Each chapter has been edited (with the author's approval) to present a balanced view of current clinical practice, and special attention has been paid to make the text easily readable.

The authors followed a tight timeline to keep the contents of the book current. As we undertook this ambitious task of editing a multiauthor, multivolume textbook, we were supported and guided by the staff at Springer; Sverre Klemp, Ulrike Huesken, Ellen Blasig, and Mahalakshmi Sathish Babu.

It is our sincere hope that readers will find as much pleasure reading this volume as we had writing and editing it. If you find *Clinical Ophthalmic Oncology* informative, it is because (paraphrasing Isaac Newton) “we have seen further, by standing on the shoulders of the giants.”

Cleveland, OH, USA

Los Angeles, CA, USA

San Francisco, CA, USA

Arun D. Singh, MD

A. Linn Murphree, MD

Bertil E. Damato, MD, FRCS

---

## Acknowledgments

To my parents who educated me beyond their means, my wife Annapurna, and my children, Nakul and Rahul, who make all my efforts worthwhile. (ADS)  
To my family, Rogel, Nancy, Gary, Gayle, and Maxine. (ALM)  
To my family, Frankanne, Erika, Stephen and Anna. (BED)





---

# Contents

<b>1 Retinoblastoma: Evaluation and Diagnosis</b> . . . . .	1
Brian P. Marr and Arun D. Singh	
<b>2 Differential Diagnosis of Leukocoria</b> . . . . .	13
Jonathan W. Kim and Arun D. Singh	
<b>3 Retinoblastoma: Staging and Grouping</b> . . . . .	29
A. Linn Murphree and Guillermo L. Chantada	
<b>4 Retinoblastoma: Epidemiologic Aspects</b> . . . . .	39
Greta R. Bunin and Manuela Orjuela	
<b>5 Retinoblastoma: International Perspective</b> . . . . .	51
Guillermo L. Chantada, Carlos Leal-Leal, Daniela C. Stefan, Santosh Honavar, and Junyang Zhao	
<b>6 Retinoblastoma Tumorigenesis</b> . . . . .	61
Michael A. Dyer and J. William Harbour	
<b>7 Retinocytoma or Retinoma</b> . . . . .	69
Arun D. Singh, Jedediah McClintic, Aubin Balmer, and Francis Munier	
<b>8 Retinoblastoma: Genetic Counseling and Testing</b> . . . . .	77
Robin D. Clark and Stefanie G. Avishay	
<b>9 Retinoblastoma: Treatment Options</b> . . . . .	89
Jonathan W. Kim, A. Linn Murphree, and Arun D. Singh	
<b>10 Retinoblastoma: Focal Therapy – Laser Treatment, Cryotherapy, and Brachytherapy</b> . . . . .	109
A. Linn Murphree and Jonathan W. Kim	
<b>11 Retinoblastoma: Intravenous Chemotherapy</b> . . . . .	119
Rajkumar Venkatramani and Rima Fuad Jubran	
<b>12 Intra-ocular Artery Chemotherapy for Retinoblastoma</b> . . . . .	129
Brian C. Tse, Rachel C. Brennan, and Matthew W. Wilson	

<b>13</b>	<b>Retinoblastoma: Intravitreal Chemotherapy</b> . . . . .	137
	Francis L. Munier and Alexandre Moulin	
<b>14</b>	<b>Teletherapy: Indications, Risks, and New Delivery Options.</b> . . . . .	147
	Thomas E. Merchant and Erin S. Murphy	
<b>15</b>	<b>Retinoblastoma: Enucleation</b> . . . . .	159
	Jonathan W. Kim and A. Linn Murphree	
<b>16</b>	<b>Histopathologic Features and Prognostic Factors.</b> . . . . .	167
	Patricia Chévez-Barrios, Ralph C. Eagle, and Eduardo F. Marback	
<b>17</b>	<b>Orbital Retinoblastoma</b> . . . . .	185
	Santosh G. Honavar	
<b>18</b>	<b>Retinoblastoma: Metastatic Disease.</b> . . . . .	195
	Ira J. Dunkel and Guillermo L. Chantada	
<b>19</b>	<b>Non-ocular Tumors</b> . . . . .	201
	Brian C. Tse, Rachel C. Brennan, Carlos Rodriguez-Galindo, and Matthew W. Wilson	
<b>20</b>	<b>Trilateral Retinoblastoma</b> . . . . .	209
	Jonathan W. Kim and Ira Dunkel	
<b>21</b>	<b>Children’s Oncology Group (COG) Trials for Retinoblastoma.</b> . . . . .	215
	Dan S. Gombos, Anna T. Meadows, Murali Chintagumpala, Ira J. Dunkel, Debra Friedman, Julie Ann Stoner, Rima Jubran, and Judith Grob Villablanca	

# Retinoblastoma: Evaluation and Diagnosis

Brian P. Marr and Arun D. Singh

## Contents

1.1	Historical Background.....	1
1.2	Clinical Presentation.....	1
1.3	Misdiagnosis.....	2
1.4	Stepwise Evaluation for Retinoblastoma.....	2
1.4.1	History.....	2
1.4.2	Initial Examination.....	4
1.4.3	Ophthalmic Ultrasonography.....	5
1.5	Examination Under Anesthesia.....	5
1.5.1	External Examination.....	6
1.5.2	Anterior Segment Examination.....	6
1.5.3	Posterior Segment Examination.....	6
1.5.4	Ancillary Testing.....	7
1.6	Neuroimaging.....	9
1.7	Counseling.....	9
	References.....	10

## 1.1 Historical Background

In 1809, a Scottish surgeon named James Wardrop wrote a monograph where he described a subset of fungus haematodes cases distinguishing them from other cases of “soft cancer,” medullary sarcoma, or inflammation. He was the first to recognize retinoblastoma (RB) as a discrete tumor arising primarily from the retina [1]. Virchow in 1864 used the name of glioma retinae because of retinoblastoma’s similarity to intracranial glial tumors. Verhoeff, in 1922, observed the retinal origin and the presence of immature, embryonic cells that formed the tumor and coined the term retinoblastoma. In 1926, the American Ophthalmological Society accepted the term retinoblastoma and the older terms, such as glioma retinae and fungus haematodes, were abandoned [2]. In 1809, it was the astute clinical observations and descriptions of the disease that made the diagnosis of what we now know as retinoblastoma.

## 1.2 Clinical Presentation

The symptoms of retinoblastoma are most often first detected by a parent or family member directly or occasionally from an abnormal light reflex in a photograph. To a lesser extent sporadic cases of retinoblastoma are first discovered by a routine pediatric exam or screening, less commonly by pediatric ophthalmologists

B.P. Marr, MD (✉)  
Department of Surgery, Memorial Sloan-Kettering  
Cancer Center, 1275 York Avenue, New York,  
NY 10065, USA  
e-mail: [marrb@mskcc.org](mailto:marrb@mskcc.org)

A.D. Singh, MD  
Department of Ophthalmic Oncology,  
Cole Eye Institute, Cleveland Clinic,  
Cleveland, OH, USA  
e-mail: [singha@ccf.org](mailto:singha@ccf.org)

**Table 1.1** Presenting features of retinoblastoma (United States)

Leukocoria or cat's eye reflex	45 %
Strabismus	25 %
Inflammatory symptoms (preseptal cellulitis)	10 %
Poor vision	10 %
Screening due to family history	5 %
Incidental detection	5 %

Modified from Abramson et al. [13]

and rarely incidentally on imaging for other conditions. In the United States and other developed nations, the most common presenting findings in intraocular retinoblastoma are leukocoria or cat's eye reflex (45 %) (Chap. 2), strabismus (25 %), inflammatory symptoms (pseudo-preseptal cellulitis) (10 %), and poor vision (10 %) (Table 1.1) [3].

For several reasons discussed elsewhere in developing nations, retinoblastoma tends to be more advanced at presentation with extraocular disease (Chap. 5). One of the major limitations to prompt treatment of retinoblastoma worldwide is access to health care. As retinoblastoma care providers, it is important for us to increase accessibility for our patients into a system that is equipped to treat this condition adequately. Community education and awareness and training of ancillary staff that are able to triage and arrange prioritized evaluations are some of the important components of this approach (Chap. 5).

### 1.3 Misdiagnosis


Histopathological studies of enucleated eyes report misdiagnosis rates from 11 to 40 %, and clinical studies of referral patterns report misdiagnosis rates from 16 to 53 % [3]. This may be attributed to many factors including rare incidence of retinoblastoma, multiple conditions that simulate retinoblastoma, the unfamiliarity of the primary health care providers, the age of presentation, and the difficulty in examining children (Chap. 2). Consequently, a thorough and detailed assessment should be done on patients suspected of having retinoblastoma.

## 1.4 Stepwise Evaluation for Retinoblastoma

A practical stepwise approach specifically to evaluate a child suspected to have retinoblastoma includes detailed history taking, initial office examination, and focused ophthalmic ultrasonography, followed by examination under anesthesia and neuroimaging if necessary (Fig. 1.1). This approach is merely a guide that can be modified as needed based upon clinical setting.

### 1.4.1 History

For a child suspected of having retinoblastoma, it is important to examine the patient and family promptly upon referral, and the initial consultation may be performed in an office setting (Table 1.2, Box 1.1). The story of how and over what time course the condition was noted, the health care professionals that saw the patient, and what was done to the child before they arrived must be recorded. A birth history including the pre- and perinatal history is important. Typically the gestational age at birth, type of delivery, birth weight, and any delivery or pregnancy complications, including infections or medications taken during the pregnancy, are noted. It is also important to inquire if any abnormalities were noted on the eye screening exam after birth or if there were any unusual birthmarks or malformations. The current history should include the child's health, any medical conditions, and environment including pets, recent trauma, or illness. For retinoblastoma suspects, the family history should include number of siblings, their health and ocular history, and any family medical disorders. It should be noted if there was any poor vision, blindness, or loss of an eye in the family. Both parents should be questioned about their ocular health and examined if no recent dilated exam has been performed. A small subset of parents of children with RB will have evidence of retinoma/retinocytoma and even unknown treated retinoblastoma (Chap. 7) [4].



**Fig. 1.1** Stepwise evaluation for retinoblastoma. This approach is merely a guide that can be modified as needed based upon clinical setting

**Table 1.2** Elements of medical history in a child suspected of having retinoblastoma

Time since onset	Duration
Prior evaluation	Prior diagnosis Prior treatment Prior surgical procedure Prior biopsy
Perinatal history	Pregnancy complications Prematurity Birth weight Type of delivery Use of oxygen
Personal history	Malformations Exposure to pets Recent trauma Systemic illness
Family history	Genetic disease Blindness Enucleation Amblyopia Retinoblastoma

**Box 1.1 Elements of fundus examination in a child with retinoblastoma**

Tumor size		
Tumor location		
Associated features	Subretinal fluid	Localized, diffuse
	Subretinal seeds	Localized, diffuse
	Vitreous seeds	Localized, diffuse

**1.4.2 Initial Examination**

The initial examination of the child can be started in the office while taking the history, by observing the comfort and behavior of the child, and noting any size, proportion, or facial abnormalities (Table 1.3). It may be possible to observe leukocoria, strabismus, or periorbital swelling and visual behavior before initiating the formal examination. Assessing the vision is dependent on the age of the patient and the amount of cooperation; however, the condition of each eye should be assessed and recorded along with the pupillary response and the presence or absence of heterochromia of the irises. A brief observation of the periorbital tissues, cornea, conjunctiva, and sclera

**Table 1.3** Elements of initial examination (office) in a child suspected of having retinoblastoma

External examination	Facial abnormalities (13q deletion syndrome) Strabismus Periorbital swelling Presence of heterochromia	
Visual acuity		
Pupillary response		
Pupillary light reflex	Normal	
	Abnormal	Leukocoria absent Leukocoria present
Anterior segment examination	May be limited	
Indirect ophthalmoscopy	May be limited	
Ultrasonography	Mass Calcification Retinal detachment Other abnormalities	

should be performed before administering dilation drops. Using a direct ophthalmoscope, the pupillary light reflex can be noted in both eyes.

Upon completion of this portion of the examination, drops for pupillary dilation can then be administered (tropicamide 0.5 % and ophthalmic phenylephrine 2.5 %). It is worth emphasizing that both eyes should be examined in equal detail. The examination of the posterior pole is best done with an indirect ophthalmoscope. Depending on the age, the child may cooperate or parents may be needed to help secure the patient while lying supine on a table or chair (Fig. 1.2). Younger children can be swaddled with a blanket or sheet. The goal of the indirect examination at this point is to confirm the suspicion of retinoblastoma and determine whether further evaluation is necessary with an exam under anesthesia (EUA). It may be necessary to place an eyelid speculum in for proper visualization of the posterior pole; appropriate topical anesthesia such as ophthalmic proparacaine 0.5 % solution should be administered before placing the speculum. A detailed fundus examination with scleral depression may be performed with an anesthetic, eyelid speculum, and restraint; however, this is fairly traumatic for both the child and the family and is generally unnecessary if a planned exam under anesthesia is possible.